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L latroductien 
Protein post-translational modification is a method 
cells use to regulate their response to external and 
internal stimulL A conunon post-translational modifi- 
cation employed in this regulatory mechanism k pro- 
rein pbospborylation. Protein phnspherylation states 
can regulate enzyme activity as well as the cellular 
location of proteins. Cells adjust the phosphate levels 
of specific proteins through the action of kinases and 
phosphatases. Phosphorylation-dephosphorylation 
mechanisms predominantly alter the state of Ser or 
Thr phosphorylation in proteins. Similar modifications 
of Tyr have only recently been studied. Although this 
review will focus predominantly on tyrosine dephos- 
pborylation, it is necessary to briefly review the history 
of tymsine pbosphoulation. Before 1980 the only regu- 
latory pbosphoamino acids identified in proteins were 
phosphoserine and phnsphothreonine. Ser and Thr 
protein pbosphorylation states regulate many metabolic 
processes (reviewed in Ref. 1). In 19~0 a unique cat- 
alytic activity was discovered while examining v-src, the 
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protein necessary for neoplastic transformation of 
chicken fibroblasts by Rous sarcoma virus. Analysis of 
this protein showed that it could phospborylate itself 
and other proteins on tyrnsine [2-4]. Analysis of cellu- 
lar phosphoamino acid content revealed that phospho- 
tyrosine accounts for only 0.01-0.05% of cellular pbos- 
phoamino acids in normal tissue culture cells [2]. How- 
ever, this content increases to 1-3% of total cellular 
pbospboan~ino acids upon transformation by oncogenic 
retroviruses [5]. The increase in tyrosine phosphoryla- 
tion upon viral transformation suggested that tyrosine 
kinases may be linked to the removal of growth re- 
straint from cells. Investigations of oncogenes from 
other tumorigenic viruses showed that many of these 
proteins also displayed tyrosine kinase activity (re- 
viewed in Ref. 6). 
The mechanism of growth factor receptor activation 
was under investigation at the same time that the 
discoveries of viral tyrnsine kinase activity were being 
made. Sm-prisingly, one of the growth factor receptors 
(epidermal growth factor) was also shown to ha~e tyro- 
sine kinase activity [7]. This identification of a non-viral 
tyrosine kinase which controi~ :e!! growth suggested 
that tyrosine phosphorylation was important in the 
physiology of non-transformed cells. 
The primary sequence of protein tyrosine kinases 
had been identified through the cloning and sequenc- 
ing of viral and cellular oncogenes (reviewed in Ref. 8). 
Progress in our understanding of tyrnsine kinases was 
rapid and the fOCUS on phnspborylation events domi- 
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hated this period of progress. Few investigators were 
attempting to understand the imvortance of tyrosioe 
deplmsphoulation events (see review in Ref. 9) i .  
Progress shm'lar to that made with the tyrosin¢ kinases 
was not possible with the protein tyrosine phnsphatases 
(PTPase, EC 3.13.48) since the pure preparation of 
PTPase and the corresponding amino acid sequence 
was not avai[ab~ until 1988 [11] when PTPase 1B was 
purified from human placenta [12]. The partial amino 
acid sequence of PTPase IB [12] yielded two surprises. 
First, tyrusine-specific phosphatase had no sequence 
s in f i l a r i t y  to any of the previously characterized serine 
and thr~.-onine phusphatases, suggesting that PTP 1B 
was a member of a different family of proteins. Second, 
a search of known protein sequences revealed that 
PTPase 1B contained a region of similarity to a major 
lymphocyte cell surface glycoprotein termed C!~5. 
C[~5 is a "receptor-like molecule" present on the lym- 
phocyte cell surface and is composed of a highly glyco- 
sylatcd, differentially spliced extracellular domain, a 
single ~ m b r a n e  domain, and a cytosolic domain 
containing two repeats of a 200-amino-acid sequence 
showing sequence identity to PTP lB. At the time this 
comparison was made, no function for CD45 had been 
determined, but studies using antibodies directed 
against its extraceDular domain suggested that CD45 
was involved in early lymphocyte activation (reviewed 
in Ref. 13). The shmlarity between CIM5 and PTPase 
IB not only suggested a function for the cytoplasmic 
domain of CD45, but also supported the idea that 
PTPases possessed a signalling function. 
1L Mulecular Mele~ ef  the PTPuses 
The initial identification of two members of the 
PTPase family (i.e, PTP IB and CIM5) led to the 
ckming of numerous other PTPases. These were ob- 
tained either through low-stringency screening of 
cDNA h'braries [14-28] or by the use of the polymerase 
chain reaction (PCR) using oligonucelotide primers 
desiga :d from conserved amino acid sequences within 
the PTPases [29-42]. Additional PTPases were identi- 
fied through sequence similarities to the conserved 
"active-site' regions of *,he PTPases (the "HCSAGVGR 
( S / T ) G '  mc,~, [_~ ,43-5o ] .  
Sequence analysis of these clones showed that they 
eitber resembled PTPase IB or CD45. PTPase IB is a 
representative of the "nonreceptor-like' class of PTP- 
ases that have only one copy of the 200-amino-acid 
conserved PTPase domain and no transmembrane 
spanning region. Fig. 1 is a schematic diagram of the 
nonreceptor-like PTPases. The diverse structures of 
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Fig. I. Primmy stru~ures of the noorecegnor-h'ke PTPase fanu'ly. 
Naraes indkmted are those fn~ published for the sequence. Refer- 
epees: PtpI |!6.17.29]. T-cell [14~,26,39], D~p61F (S. McLaughlin. 
personal c o ~ u n ~ ) .  ~ [42]. Rpipstep [24]. Hptplc 
[25,40,41]. n~pHl [34]. ~ [33]. P~pl [31], Yseptpl [32]. 
Yscptp2 [96]. YopSl [20]. Vhl [49]. Hcdc25 [48], Yspcdc25 [44], 
Hesgptp 15o]. 
these molecules suggest multiple methods of regula- 
tion. CD45 is a representative of_ the "receptor-like" 
class of PTPases that have, with two exceptions (PTPase 
/3 [23]; and DPTP10D [36,37D, tandem 200-amino-acid 
PTPase cytnso]ic repeats and variably sized extracellu- 
lar domains separated by a single transmembrane 
spanning region. A review on the qructore and poten- 
tiai function of these receptor-like molecules has ap- 
peared [51~ 
The primary structure of 42 PTI ases has allowed us 
to construct a family tree by sequence comparison. 
This tree, created by performing multiple progressive 
sequence alignments of each 200-amino-acid conserved 
region (blackened area in Fig. 1) and clustering related 
sequences [52], provides a non-biased grouping of the 
PTPases. The result, shown in Fig. 2, illustrates the 
relationship of all of the PTPases. In general, the 
PTPases can be devided into three subfamilies. The 
receptor-like PTPases form one subfamily while the 
non-receptor-like class of PTPases can be further di- 
vided into additional subfamilies. Approx. 18 nonre- 
ceptor-like PTPases group together. PTPl and PTP 1B 
are prototypes for this subfamily. A second branch of 
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Fig. 2. Fam~ tree of t~  PTPases. lriTase domains were atigned by 
i,ogress~ alignment method of Fcn~ and Doo~u~ [521 using the 
PILEUP i~gram of the W'r~me~ Genetics Program ~ersinn 7.0 
[l12j. Only PTP~e domains and not flanking sequences were input 
for the analvs~ Nantes of the PTPases are those filst i~blis~hed f,'~r 
the sequence. References: tfi:dc25 148]' Ysix:dc25 [44]. Vhl 149~ 
HI~pl [17,29]' RVOI ll6]' UtceU ll4.39]' Rl~PS [26], MtceU 139]. 
Dptpl (S. McLaughlm~ personal c~munic~tinn ). Hheptp [42], RI~p- 
step 124], Hptplc [25,40], Rshl~pl [41], Mhcp 140]. Hplphi [34], 
H~lm~eg [33], Hl~7.eta [23]. RI~pl8 12O], Hl~betakn [21]. 
H~pgamma [21.23]' D~iOga 136-38]. M~145 [45]' I~J:d45 [43]. Hcd45 
[46]. tBar [47], Rlar 128]. Hi~lxlella [23]. Dlar [15], UPtl~pha 121- 
2330]. Mlrpa [18.19], UPll~loa [23]' Hrl~pmu [35]. Hrptlmm 135]. 
Hpt#oetal~" [23]. Mptpbetakr [35"]. Dlapl0d [3637], DIdO [IS]. P,~t 
[31]. Yseptpl [32]' Hestplp [50]. Yscplp2196]. Yop5l [20]. 
this subfamily includes the caccinia virus phosphatase 
(Vhl) as well as edc25. Since the vacdnia gene encod- 
ing the phosphatase was the first member of this sub- 
family to be identified, we have referred to this group- 
ing as the Vhl subfamily of phosphatases. It appears_ 
that ve~  early in evolution the two nonzeceptor-like 
groups diverged from each other, interestingly, Vhl is 
a phosphatase which catalyzes the removal of phos- 
phate .from both serine, threonine, and tyrosine ([49]; 
Guan et al., unpublished). Results similar to those 
presented here were described by Krueger et al. using 
a much smaller database [23]. 
One difficulty that has arisen due to the rapid 
cloning of PTPases is the lack of a defined system of 
nomenclature. For example, there are two different 
reports of clones named PTPase a,/3 and 3' [21,23]. By 
chance, both a and 3' are identical but, as seen in Fig. 
2, a subscript is needed to differentiate the two /3 
molecules. Some discussion of a nomenclature system 
has taken place at the Annual Protein Phosphamse 
meeting in Brussels (Sept. 1991). Even though no final 
system of nomenclature was adopted, a naming system 
using 'R'  as a prefix for receptor-like molecules and no 
'R'  for nonreceptor-like molecules was suggested. It 
was further proposed that each PTPase would be given 
a unique number or letter (or both) assigned in the 
order cloned. Therefore, with this system, CIM5 would 
be renamed RPTPase 1, and PTPase 1B would be 
called PTPase 1. No matter what system is chosen, 
some method of systematic nomenclature is badly 
needed. 
As Fig. I indicates, most PTPases contain function- 
ally important sequences other than the conserved 
200-amino-acid PTPase domain. By comparison of 
these sequences with other known protein sequences 
potential functions can be suggested for these regions 
of the PTPases. When human LAR was cloned [47], 
both the intraccllular and extracellular domains had no 
known function. The cytoplasmic domain's similarity to 
PTPase IB suggested a function for this part of the 
molecule. Streuli and collaborators, upon analysis of 
the extracellular region of this molecule, noted that it 
possessed similarities to the ligand-binding region of 
the neural cellular adhesion molecule, N-CAM. Extra- 
cellular regions of N-CAM interact in a homophilic 
manner to influence neuronal development [53]. Since 
LAR is expressed on the surface of all solid type 
tissues and contains within its cytoplasmic domain a 
phosphatase region, this molecule is proposed to be 
responsible for the contact inhibition of cell growth 
[15]. Homophilic interactions between LAR molecules 
located on adjacent cells may cause an increase in 
LAWs phosphatase activity, a decrease cellular ph~-  
pbotyrosine content and may thus stop cell growth. 
Although this is a particularly attractive suggestion, it 
should be pointed out that we have a very poor under- 
standing of the function of the extra~ellular domain of 
the PTPases. 
Another sequence similarity that was discovered 
within the Fl'Pases is in the SH2 domains of PTPlc 
[25,40,41]. Research by many groups has shown that 
these 100-amino-acid regions specifically bind tyrosine- 
phosphorylated proteins (reviewed in Ref. 54). Analysis 
by Sben and coworkers has shown that the SH2 do- 
mains of PTPlc are functional [25]. This suggests that 
PTPlc may use these regions to bind substrates or  
Ioeafize to specific subceHular locations, as suggested 
for other SH2-containing proteins [55]. Two other PTP- 
ases, Hptpmeg and HptpHI, contain a region that 
shows 20-35% similarity to a region contained in :hree 
cytoskeletal proteins, band 4.1, ezrin and talin [33,34]. 
These regions in these cytoskeletal protvins are ncces- 
s a ~  for asso~-iation with other cytoskeletal proteins. 
Therefore this similarity suggests that the two lrrPases, 
termed Hpipmeg ane  HptpHI, use these sequences to 
localize themselves to the cytoskeleton and thereby 
define specific substrates for these PTPases. 
Specific amino acid sequences located near the C- 
terminus of  several of  the noareceptor-like FIVases 
appear to be important ha subceHular localization of  
the phosphatases. Since these sequences appear to play 
important roles ha the intraceHular localization of the 
PTPases, they h'kely function to define or limit the 
substrate specificity of  the PTPases. DetaiLs of these 
C-terminal sequences and their function will be da- 
scribed later in this review (see Section IV, Biology of 
the 7FPases). 
The gene expression pattern of PTPases also sug- 
gests specific function. Many of the PTPases are Oroadly 
distributed ha various cell t ~ e s ;  others, however, have 
quite specific extnession patterns. C I ~ 5  has long been 
known to be expremed only in lymphocytic cells [13]. 
The striatum enriched phosphaLase, as its name ira- 
is expressed in a highly selective manner  in the 
brain's striatum [24]. Selective expression of three 
Drosoph/la receptur-like PTPases in embffonal central 
ne rmus  system axons suggests their role in axon out- 
growth and guidance [36-38]. PTPase 1 is strongly 
expressed in the hippocampus [16], a region of the 
brain known to be important ha long-term potentiation 
and memory. In-situ staining fur PTPase activity ha the 
brain using o-phoxpho-L-t3~a~ine as a substrate [56] 
confirmed that the hippocampus is a region of the 
brain rich in PTPases. 
I lL Stractare and fw~fioa stadie~ of the PrPases  
Expression of cloned PTPases in a variety of  
prokat3~m~ and eukaryotic .systems has provided suffi- 
cient quantities of  protein for structure/function stud- 
ies. Using the large database of PTPase sequences, 
highly conserved residues within the PTPase family can 
be identified and mutated to examine their importance 
in catalysis and stability. Deletion mntagenesis can be 
used to determine the importance of vario:=s ~gions  :,f 
the molecule. Finally, kinetic analysis and chemical 
modification of the PTPases can he used to evaluate 
their mechanism(s) of  catalysis. 
Two sequence motifs present in kinases and deby- 
drogenases appear to he conserved in many of the 
phosphatases. The fu'st sequence is the GXGXXG 
motif in the "active-site region" [HCSAGVC'-R(S/TK;] 
of  the PTPases. As noted by Pot et al. and Guan et al. 
[2832], this motif is also present in dehydrogenases [57] 
and protein kinases [58] and is located at or  near the 
active site of  these enzymes. Modification of the first 
glycine ha the sequence to any other residue eliminates 
human LAR PTPase activity [59] suggesting that the 
motif is critical to p.hosphat.~se structure or  functi,,n. 
The lnesence of  this motif suggests that structural 
features within this region of  :he PTPases are similar 
to structures of  either the dalrydrogenases or the ki- 
nases. It has recently been noted that the GXGXXG 
motifs are tuuetionally different ~Ja dehydrogenases and 
kinases [60], It will be interesting to determine the 
functional role of  this motif ha the PTPases. 
The. seared conserved motif, that appears in the 
T-cell and PTPase 1 subfamily of the nonoVhl-like 
PTPases, is the FKVRES sequence [28]. This sequence 
is located just  ups t ream from the conserved 
"HCSAGVGR(SfDG" motif of  the PTPases. The 
FLVRES sequence corresponds to the most highly 
conserved region of the phosphotyrusine-binding SH2 
domain of the Src t~Tosine kinase family [54]. The 
FLVRES sequence ha c-src may be associated with 
cell-specific oueogenes~ as mutation of these residues 
modifies the transformation pattern of  two cell lines 
from different species [61.62]. It is tempting to specu- 
late that PTPases that contain this sequence, which is 
invariably located close to the active site of  the PT- 
Pase, also utilize these amino acids in phosphotyrosine 
binding. 
Because p h o s p h o e ~ i n e  content of  cells is maxi- 
mally 3% of total cellular phoxphoamino acids, even in 
transformed cells [5], the natural substrates for the 
PTPases are rare. Therefore most studies of  PTPases 
use proteins that are readily avm'lable in pure form and 
easily phosphorylatcd on t~rusine. These include pro- 
teius such as casein, h i .one ,  myelin basic protein, and 
.~iys~.yrne as well as small peptides such as poly (Glu4, 
Tyr), and anglotensin. All substrates are generally 
phoxp.horylated on q a ~ i n c  in vitro using purified tyro- 
sine kinases. The use of  these 'artificial" substrates has 
made it pos~'ble to rapidly analyze the kinetic proper- 
ties of  the PTPases. However, the use of ar t i f~al  
substrates limits our under~anding of the "naturally" 
occuring substrates of  the PTPases. Recently, several 
studi,~ of  the PTPases on naturally occuring substrates 
have been repotted. All but the Vhi  family of 
phosphatases catalyze the removal of  phosphate from 
~osLn_e and not serine- or  threoniue-containing sub- 
strates. Demonstrating serine and threonine phos- 
phat~.~ activity in the ~"ui i'~tdiy c~ P'l'Pases first 
documented that this family of enzymes did not have a 
tyrusinc-restricted substrate specificity, in addition, the 
fact that Vhl showed sequence identity to cdc25 pro- 
vided the fu-st suggestion that cdc25 was a phosphatase 
which tamld dephosphorylate p34 'x~. The sequence 
similarity between the two molecules also provided a 
rationale for testing the phosphatnse activity of  cdc25 
in vitro and in vivo [63,64]. 
The insulin receptor tyrosine kinase has been an 
attractive 'naturally" oomring substrate for the PTP- 
ases. Autopbospbofflation of  the insulin receptor /t 
subunit specifically in the region surrounding amino 
acid 1150, activates the insulin receptor to phospho- 
rylate other cellular proteins on tyrosine [65]. The 
regulatory 1 150 region contains three tyrosines, all of  
which must be pbosphor~ t ed  before trans-kinase ac- 
tivity is poss~le. Levine and coworkers have estab- 
lished that soluble insulin receptor kinase phospho- 
rylates a ~eptide containing these tyrosines in the 
order 1150, 1151, 1146 [66]. Differences in the dephos- 
phorylation of  these tyrosines by four tyrosine phos- 
phatases, human T-cell PTPase, human PTPase 113, 
human CIM5 and rat LAR, on the same triphosphory- 
lated peptide, have recently been described [67]. The 
two receptor-like pbospha t a s~  CD45 and LAR, re- 
move the phosphates in the rate-dependent order 1146 
> 1151 > 1150, essentially reversing the order of  phos- 
photajlation. PTPase IB removes the phosphates in 
manner, 1150 = 1151 > 1146. T-cell PTPase displays no 
order of  dephusphorylation, removing all phosphates at 
the same rate. These data implicate substrate speci- 
ficity as being an important determinant in PTPase 
catalysis and regulation of  substrate specificity. Kinetic 
studies by Cho et al. [68] support the observations of  
Ramachandran and workers [67]. They observed that 
the first domain of  human LAR dephosphorylates 
p h o s p ~  1146 at least 25 times more efficiently 
than tyrosine 1150 and 1i51 [68]. 
Many compounds modulate the activity of  protein 
tyrosine phosphatases. Probably the most universal is 
orthovanadate, which effectively inhibits all tyrosine 
phosphatases so far tested at levels between 10 and 100 
/tM. Another unF.~..sal inhibitor is molybdate. Polyan- 
ionic spermine and spemidine, EDTA, Mn 2+ and Zn 2+ 
differentially inhibit the PTPzs~  and can be used to 
discriminate between phosphatases [28,69-71]. From 
the first purification of PTPases it was noted that thiol 
reducing agents must  be present during their extraction 
and isolation to preserve their activity [28,69,72]. This 
suggested that a cysteine residue was critical for en- 
zyme activity. To pursue this further, su!phyd~l-di- 
rected inhibitors were tested for their ability to inhibit 
PTPase activity. Pot and coworkers showed that three 
irreversible inhibi to~ N-ethyimaleimide, p-(bydroxy- 
mercuri)benzoate and iodoacetate fully inln'bited rat 
LAR's PTPase acthdty [28]. Equivalent levels of  iodo- 
acetamide had no effect on enzyme activity. Analysis of  
enzyme inactivation at different pHs indicated that the 
negatively charged iodoacetate interacts with a positive 
residue at or near the active site of  rat LAR, allowing a 
reactive cysteine to attack and displace 1- from 
iodoacetate. This was confirmed by experiments using 
purified rat LAR and ~4C-iodoacetate. lodoacetate 
binds rat LAR and the binding is in competition with 
the substrate. Following the irreversible inactivation of 
LAR with iodoacetate a stoichiometry of  0.8 mol of  
indoacetate bound per mol of  enzyme could be demon- 
strated [73]. A single 14C-labelled peptide was isolated 
following proteolytic digestion of LAR, and sequencing 
of this peptide identified the site of  labelling as cys- 
teine 1522, the catalytically essential residue within the 
central conserved 'HCSAGVGR(S/T)G" PTPase mo- 
tif. Although there are 11 Cys residues in this protein, 
only Cys-1522 is labelled, pointing to the unusual reac- 
tivity of  the active-site thiol residue. 
The regulatory effects of  phosphorylation on PTP- 
ase activity have been examined. CD45 can be readily 
phosphorylated on ser ine/ threonine by casein kinase 
2, protein kinase C, and glycogen synthase kinase 3 in 
vitro, and on tyrusiue in vivo, but no change in pbos- 
phatase activity could be detected [74,75]. Rat LAR is 
also phosphorylated in vitro by protein kinase C and 
p43 v"~ tyrosine kiuase but no change in activity was 
noted with either phosphorylation [28]. The only in vivo 
study showing regulation of a phusphatase by pbospho- 
rylation was done by Ostergaard ~nd Trowbridge [76]. 
They showed that when T-cells were treated with the 
calcium ionophores ionomycin or A23187, CD45 PTP- 
ase activity decreased by 50-90%. Analysis of  the 
CD45 showed that the drop in activity correlated with 
a drop in serine phospho~iation. Even though the sites 
or enzymes responsible for this dephosphorylation were 
not k2entified, this was the first indication that PTPase 
activities are regulated by pbosphorylation in vivo. 
The large database of similar PTPase sequences 
enables conserved residues to be identified and mu- 
tated to determine their importance in the catalysis of  
the enzyme. Systematic mutagenesis of  conserved cys- 
tein residues in the catalytic domains of CD45 by 
Streuli and coworkers indicated that only the first 
domain catalyzed the dephospborylation of substrate 
[15]. Later, a similar conclusion was obtained for hu- 
man LAR [59]. In this same study other point muta- 
tions in the central "HCSAGVGR(S/T)G'  motif were 
created, identifying the critical importance of this re- 
gion to catalysis. Pot et al. [28] confirmed that greater 
than 99% of the activity on the substrates tested arises 
from the first domain of purified recombinant LAR. 
Either the second domains of CD45 and LAR act 
solely in a regulatory manner or appropriate substrates 
for these domains have not been found. Recently both 
domains of human PTPa have been shown to contain 
catalytic activity [71]. Differences in substrate speci- 
ficity, responses to modulators and the interdepen- 
dence of these two domains are properties likely to be 
found important in the action of PTPa in vivo. 
The ability of  a single amino acid mmation to inacti- 
vate the PTIPase has been a useful negative control for 
PTPase function, both in vitro and in vivo. Mutation of 
the ojsteine contained in the central PTPase signature 
motif was used to establish the specificity of  PTPase I 
[77], LAR [28], cdc25 [63,64], the bacterial PTPase in 
vitro [20], and in vivo [78]. This unique and simple 
raethod should be of great utility in future studies of  
the functional significance of PTPases. 
Random chemical mutaganesis has also been uti- 
lized to study the stability of PTPases. Tsai and 
coworkers, using hydrox3"lamine and N-methyl-N: 
nitro-N-nitrosogoanidine, mutated the first cytoplasmic 
PTPase domain of human LAR and screened for tem- 
perature-sensitive and thermostable mutants [79]. This 
anal~is  identified 8 temperature-sensitive mutants 
~l~-tcred in ae 8 0 - ~ a c i d  r e , o n  in the first half of  
the molecule. The grouphtg of these temperature-sen- 
sitive mutants identified a region of this PTPase, highly 
conserved in other PTPases, that probably is critical for 
initial folding and stability of  the protein. Interestingly, 
a mutation that causes increased stability and solubility 
of  temperature-sensitive human LAR mutations 
(C1446-Y) occurs naturally in the rat homologue of 
LAR and may account for the excellent solubility and 
stability of  the latter enzyme [2S]. 
The studies descn'bed abo~e all suggest that the 
c~teine in the "HCSAGVGR(Sfff)G' motif is an im- 
portant residue used by PTPases to remove phosphate 
from phosphoprotains. Kinetic and chemical analysis of  
the action of PTPases has allowed a probable mecha- 
nism of enzyme action to he identified. Guan and 
Dixon [77] and Pot et at. [28] utilized a rapid denatura- 
tion technique to trap a radioactively lahelled phospho- 
cysteine i~termediate of  rat PTPase I and L0,R. For- 
mation of this intermediate was transient and depen- 
dent nn the presence of the catalytically important 
cystaine. Walsh and his colleagues have also detected a 
32P-labelled phosphoprotein and have eloquently docu- 
mented an LAR PTPase catalyzed tsO exchange into 
phosphate from water [80]. Collectively, these observa- 
tions along with work of Zhang and Dixon (unpub- 
lislmd) point to the PTPases utilizing the suggested 
mechanism outlined in Fig. 3. The nucleophilic cys- 
teine (of the PTPase signature motif) attacks the phos- 
phate of  the phosphotyrosinc protein substrate, releas~ 
ing the dephosphopjlatad protein substrate and form- 
ing a thiolphosphata enzyme intermediate. In the sec- 
ond step of the reaction~ wat.er ~ttacks this intermedi- 
ate, regenerating active enzynm and releasing the sec- 
ond l:.-nyJuct, inorganic phosphate. Kinetic data and 
"trapping" of the phospho-enzyme intermediate sug- 
gests that the second step in the reaction is rate detar- 
mining. 
IV. m o l e ~  ef  the PTPases 
Only a few of the PTPases have a well characterized 
biological function. Information about PTPase function 
has been obtained from 'mutant" cells lacking the cn- 
z~ne. CD45 ~s e.~l~ressed on the cell surface of iympho- 
cytes and efforts were directed at the selection of cell 
lines lacking this surface marker. Because CD45 is 
c r i tk~  to T-cell activation, cells lacking functional 
receptor PTPase have impaired response to T-cell 
[81,82], CD2 [83], and B-cell receptor stimuli [84]. 
Intracellular signals induced by C'I~5 in T-cell activa- 
tion include phosphoinositol turnover [85] and regula- 
tion of cellular serinL- kinases and phosphatases [76]. 
Three reviews regarding; "he biological activit7 of  CD45 
have recently appeared4 [86-88]. 
Another PTPase wl.,me biological significance is 
known is the Yers/n/a Yop2B phosphatase. Sequence 
comparison of the catab tic core of  m ~ m a l i a n  PTPase 
slur, red that the bacterial Yop protein shared a num- 
her of  invariant residues with the lrfPases. Expression 
of the bacterial protein led to the discovery that it had 
phosphatase activity [20]. Honmlogous recombination 
of the genes encoding catalytically active and inactive 
enzymes conclusively showed that removal of  this PTP- 
ase activity renders the bacteria avirulent [78] support- 
ing the important observation that the phosphatase 
o o. o 
O--P~OH "l" E S-" ~ --O-P--OH - -  ~ E--S~P--OH ESH 4- 
ESH 
Fig. 3. Suggested m~chanism for protein tyresine phosphatase. E-SH represents the enzyme with the catablic Cys residue. E-S- denotes the 
thio| anion of the PTPase which appears to the reactive form of the enz~3'ne. E-S- PO4H is the phosphoenz,~ne intermediate. 
activity is essential for virulence in the pathogen which 
causes diseases such as the plague or the black death. 
For some time it had been known that p34 '~2, a 
scr ine/ thrconinc kinase contained in the mitosis-pro- 
moting factor (MPF) complex of higher eukaryotes, 
was negatively regulated by tyrosine and serine phos- 
phorylation (reviewed in Ref. 89). Genetic dissection of 
the system had identified a positive regulatory factor, 
termed edc25, that could induce the dephosphorylation 
of cde2 and taos entry into the cell cycle. Yeast mu- 
lants that lack active cdc25 can be induced to enter the 
cell cycle by the introduction of  human T-cell PTPase 
[90:;. Thcrcfc,rc tyrosinc phosphatase activity was 
thought to be contained in or  activa:ed by cdc25. 
Identification of Vhl [49] gave further impetus to this 
idea. Alignment of  Vhl to edc25 (noted by Morcno 
and Nurse [91]) showed discernible homology, espe- 
dally in the acth,-e-site region of the PTPase. This 
observation triggered several groups to test the phoP 
ph=tase activity of  purified cdc25, cdc25 has a low-level 
phosphatase activity toward a very narrow set of  sub- 
strates [63,64,92.93]. In all cases, p34 ' ~  was activated 
by removal of  phosphate from its regulatory tyrosine. 
Parallel research has led to the identification of a 
PTPase, p65, that has both serine and tyrosinc phos- 
phatase activity. This protein is a mitosis-specific com- 
ponent of  human MPF [94]. Purified mitotic 1365 shows 
activity towards phosphotyrosine poly(Glu,Tyr) and ser- 
ine/threonine-phosphorylated histone and phospho- 
wiase a [95]. Further evidence supports the identity of  
this protein as the gene product of  cdc25 [95]. The size 
difference between tbe predicted 54-kDa human cdc25 
[48] and 65-kDa 1365 can presumably be accounted for 
by the latter's O-glycosylation. Conclusive identifica- 
tion awaits testing of  both proteins with specific anti- 
bodies. 
During the search for a PTPase responsible for 
activating p34 ' ~ ,  two PTPase homologs from S. pombe 
and S. cereL-/s/ae were cloned and characterized [31,32]. 
Tyrosine phusphatase activity was demonstrated for 
one of these PTPases [32]. Recently, Guan et al. [96] 
has reported the cloning of another S. ceret'isiae PTP- 
ase. Ota and Varshovsky [97] have also shown that this 
S. cerevisiae PTPase plays a role in the ubiquitin path- 
ways that are important in protein degradation and in 
DNA repair. 
Because of  the growth activating and oncogenic 
functions of  tyrosine kinases, the action of protein 
tyrosine pilosphatases functioning as tumor suppressor 
genes has also been considered. LaForgta and cowork- 
ers pursued this pos~i l i ty  by determining if there was 
a correlation between deletion of the genc for human 
PTP7 and the presence of tumors in humans [98]. 
Results indicated that one allele of  the genc was lost in 
3 of  5 renal carcinoma cell lines and 5 of 10 lung 
carcinoma lines. Other Fl 'Pase genes have been 
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mapped to regions of chromosomes with frequent ab- 
normalities associated with human cancer [35,40]. 
Another method used to identify potential functions 
of PTPases is to introduce these cata!~sts into cells and 
then to evaluate the biological effects of  the PTPases. 
Biological effects observed, using this approach include 
blockage of insulin-like growth factor ! receptor auto- 
phosphorylation in Xenopus oocytes [99], induction of 
meiotic cell division in Xenopus oocytes [100], reduc- 
tion in baby hamster kidney cell growth rate [101], 
stimulation of Ca2+-dependent amylase secretion from 
pancreatic acini [ 102], reduction of transcriptional acti- 
vation endowed by AP-I or CREB transcription factors 
[27], and a reduction in the number of  v-src [103] and 
p185 he° [104] transformed foci in NIH-3T3 cells. The 
exact position where each of these PTPases acts to 
produce these effects is unknown. 
Expression of the PTPases in ceils have highlighted 
aspects of  their cellular distributions. Cool and cowork- 
ers noted that most of the T-cell PTPase overexpressed 
in baby hamster kidney cells was associated with the 
insoluble membrane fraction [101]. Similar results were 
seen when the same PTPase was expressed in bac- 
ulovirus [105], where Triton X-100/KCI extractions 
were necessary to remove the enzyme activity from the 
cell pellet. Both results suggest a localizatiol: of  T-cell 
PTPase to the membrane fraction, possibly through the 
hydrophobic amino acids at its Coterminus (see above). 
Results with human PTPIB are similar. Full length 
forms of ~he enzyme could only be isolated when the 
membranes were. solubilized in 2% Triton X-100 [106]. 
When PTPI was introduced into NIH 3T3 cells the 
protein was shown to localize to the endoplasmic retie- 
alum and solubility studies indicate that PTPl had 
properties of  an integral and not a peripheral mem- 
brane protein [103]. Recent observations by Neat and 
his colleagues indicate that the last 35 residues of PTP 
IB are responsible for this localization to the mem- 
brane [107]. Other studies have indicated novel cellular 
distributions of PTPases. These include the shift of  
different sized PTPase activities from the particulate to 
soluble fractions in megakaryocytic differentiating K562 
cells [108], a redistribution of CD45 from the Golgi to 
an unidentified intracellular location upon T-cell acti- 
vation [109], and the apparent movement of  kidney cell 
PTPase activity from membranes to the cytosol upon 
cell coufluency, with a concomitant decrease in molec- 
ular weight and increase in activity [110]. A general 
activation of low-molecular-weight membrane tyrosine 
phosphatase activity has also been described by Pallen 
and Tong in density-dependent growth-arrested fibrob- 
lasts [111]. 
V. Concluding remarks 
Knowledge of the protein tyrosine ph~sphatases has 
increased dramatically over the last year with the 
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cloning of  new cDNAS, the analysis of  reccanbinant 
proteins '  actions on substrates in vitro, deletion analy- 
sis of  known PTPases in vivo to de termine  biological 
function, and the evaluation of  tyrosine phosphatasc 
effects when introduced into a complex cellular system. 
I t  is a diverse and growing family with complex and not 
yet fully understood functions. It  wculd appear  that  the 
proteins will have to be highly regulated,  since most  
Hkely multiple PTPases will most  likely occur in the 
same cell. The  availability of  cloned genes, pure  pro- 
teins, and antibodies to these proteins will give future 
researchers  the toois necessary to continue exploration 
of  this interesting and complex family of  regulatory 
proteins. 
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